GlassScriptPhysician profile
David S Rho
NPI 1932106440
$4,812.63
in general payments reported to CMS, 2019-2025
28 companies · $1,383 in 2025
The $1,383 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $151 · 2021: $508 · 2022: $662 · 2023: $565 · 2024: $1,097 · 2025: $1,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,769 · Consulting Fee: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,769.26 |
| Consulting Fee | $275.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,807.77 | 2019-2025 | Eylea Hd, Eylea |
| Oyster Point Pharma, INC. | $339.58 | 2022-2025 | Tyrvaya, Ryzumvi |
| Astellas Pharma US INC | $279.82 | 2024-2025 | Izervay |
| Cardinal Health 110 LLC | $275.00 | 2025 | |
| Alcon Vision LLC | $252.42 | 2025 | Argos, Clareon Panoptix Pro, Tryptyr |
| Sandoz INC. | $207.33 | 2024 | Cimerli |
| Harrow Eye, LLC | $176.86 | 2024-2025 | Vevye, Triesence |
| Horizon Therapeutics Plc | $161.49 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $136.73 | 2019-2022 | |
| Coherus Oncology, INC. | $132.83 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $126.55 | 2019-2025 | |
| Merz Pharmaceuticals, LLC | $126.29 | 2021-2025 | Xeomin |
| Alimera Sciences, INC. | $118.19 | 2019-2024 | Yutiq, Iluvien |
| Bausch & Lomb Americas INC. | $100.94 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $83.22 | 2024-2025 | Xdemvy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $70.26 | 2019 | |
| Apellis Pharmaceuticals, INC. | $69.04 | 2022-2025 | Syfovre |
| Ani Pharmaceuticals, INC. | $57.07 | 2025 | Iluvien, Purified Cortrophin Gel, Yutiq |
| Dompe US, INC. | $56.40 | 2022-2025 | Oxervate |
| Genentech USA, INC. | $52.81 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $44.72 | 2019 | |
| Abbvie INC. | $33.49 | 2023-2024 | |
| Allergan, INC. | $30.12 | 2019-2022 | |
| Rayner Intraocular Lenses Limited | $26.01 | 2023 | Rayone Emv, Rayone Aspheric, Omidria |
| Biotissue Holdings INC. | $18.00 | 2023 | |
| Thea Pharma INC. | $15.24 | 2025 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $14.45 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.